国泰海通证券：维持联邦制药(03933)“增持”评级目标价15.53港元

智通财经网04-13

智通财经APP获悉，国泰海通证券发布研报称，随着原料药业务逐渐走出周期底部，主业利润有望重拾增长，同时核心管线UBT251在海外合作方诺和诺德(NVO.US)持续推进下，联邦制药(03933)创新管线价值有望逐步兑现。预测公司2026-2028年EPS为0.55/0.81/1.00元，增速为-48%、49%、23%。该行参考可比公司，给予2026年归母净利润25倍PE估值，给予目标价15.53港元...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2627438797?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/image/20260413/20260413160030_16700.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","is_english":false,"pubTime":"2026-04-13 15:59","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2627438797","market":"hk","top_or_hot":-1,"title":"国泰海通证券：维持联邦制药(03933)“增持”评级 目标价15.53港元","media":"智通财经网","content":"<div>\n<p>智通财经APP获悉，国泰海通证券发布研报称，随着原料药业务逐渐走出周期底部，主业利润有望重拾增长，同时核心管线UBT251在海外合作方诺和诺德(NVO.US)持续推进下，联邦制药(03933)创新管线价值有望逐步兑现。预测公司2026-2028年EPS为0.55/0.81/1.00元，增速为-48%、49%、23%。该行参考可比公司，给予2026年归母净利润25倍PE估值，给予目标价15.53港元...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1427696.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>国泰海通证券：维持联邦制药(03933)“增持”评级 目标价15.53港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n国泰海通证券：维持联邦制药(03933)“增持”评级 目标价15.53港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-13 15:59 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1427696.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，国泰海通证券发布研报称，随着原料药业务逐渐走出周期底部，主业利润有望重拾增长，同时核心管线UBT251在海外合作方诺和诺德(NVO.US)持续推进下，联邦制药(03933)创新管线价值有望逐步兑现。预测公司2026-2028年EPS为0.55/0.81/1.00元，增速为-48%、49%、23%。该行参考可比公司，给予2026年归母净利润25倍PE估值，给予目标价15.53港元...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1427696.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EWH","symbol_name":"香港ETF-iShares MSCI","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1427696.html","article_id":"2627438797","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/image/20260413/20260413160030_16700.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627438797","pubTimestamp":1776067193,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"该行认为，联邦制药有望通过深化垂直整合产业布局，发展多元业务，丰富产品矩阵，推进制剂、原料、动保、研发互补协同发展，维持稳健的现金流动性，积极应对市场变化，逐渐走出周期底部。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"161027":"证券","EWH":"香港ETF-iShares MSCI","03933":"联邦制药","02611":"国泰海通"},"translate_title":"Cathay Haitong Securities: Maintain \"Overweight\" Rating of United Laboratories (03933) Price Target of HK$15.53","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161027":1.5,"02611":1.5,"03933":1.5,"EWH":1.5},"content_text":"智通财经APP获悉，国泰海通证券发布研报称，随着原料药业务逐渐走出周期底部，主业利润有望重拾增长，同时核心管线UBT251在海外合作方诺和诺德(NVO.US)持续推进下，联邦制药(03933)创新管线价值有望逐步兑现。预测公司2026-2028年EPS为0.55/0.81/1.00元，增速为-48%、49%、23%。该行参考可比公司，给予2026年归母净利润25倍PE估值，给予目标价15.53港元，维持公司“增持”评级。国泰海通证券主要观点如下：周期性业务逐渐筑底，静待走出周期底部2025年中间体销售下降39.4%至16.12亿元，分部利润率10.8%，原料药销售下降23.1%至49.0亿元，分部利润率5.6%。该行认为，联邦制药有望通过深化垂直整合产业布局，发展多元业务，丰富产品矩阵，推进制剂、原料、动保、研发互补协同发展，维持稳健的现金流动性，积极应对市场变化，逐渐走出周期底部。多个重点创新药项目正积极推进对外授权合作，核心管线UBT251海外顺利推进2025年，联邦生物与诺和诺德达成GLP1R/GIPR/GCGR三靶点激动剂UBT251独家许可协议，海外合作方诺和诺德已于2026年一季度启动针对超重/肥胖1b/a期临床研究，计划于2026年下半年启动针对2型糖尿病期临床研究，预期2027年临床数据读出。公司其他重点在研项目，如新型多肽美受体(神经肽Y2R)激动剂注射用UBT37034，超重或肥胖适应症已获中、美国临床批准，2026年3月完成中国Ⅰ期首例受试者入组。口服GLP-1R小分子激动剂UBT48128口服制剂，预计2026年提交中美临床申请。制剂业务呈现结构性增长，胰岛素放量迅速，国际化布局加速胰鸟素系列收入同比增长57.4%至19.46亿元，胰鸟素产品中标巴西卫生部采购标单，出口量创中国同类产品出口纪录。人用制剂实现出口创收5.54亿元，已与多个一带一路国家及新兴市场客户达成业务合作，加速产品注册与商业化落地。风险提示原料药价格波动风险，创新药临床研发失败风险，海外授权管线推进力度不达预期风险，政策风险。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2627438797","isCrawlerRequest":true}

国泰海通证券：维持联邦制药(03933)“增持”评级 目标价15.53港元

精彩评论

国泰海通证券：维持联邦制药(03933)“增持”评级目标价15.53港元